Novel non-neuroleptic phenothiazines inhibit mycobacterium tuberculosis replication

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1551-1558

  Salie, Sumayah ^a   Hsu, Nai Jen ^a   Semenya, Dorothy ^b   Jardine, Anwar ^b   Jacobs, Muazzam ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Antimycobacterial; Chemotherapy; Dopamine; Serotonin; Thioridazine

Indexed keywords

ALIPHATIC AMINE; GREEN FLUORESCENT PROTEIN; ISONIAZID; PHENOTHIAZINE DERIVATIVE; PTZ 3; PTZ 31; PTZ 32; PTZ 4; THIORIDAZINE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; PHENOTHIAZINE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; GROWTH INHIBITION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PHENOTHIAZINES;

EID: 84903205212     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku036     Document Type: Article

References (33)

1. WHO. Executive summary. In: Global Tuberculosis Control. Geneva: WHO Press, 2011; 1-2.
2. Koul A, Arnoult E, Lounis N et al. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-90.
3. Amaral L, Boeree MJ, Gillespie SH et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35: 524-6.
4. van den Boogaard J, Kibiki GS, Kisanga ER et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-62.
5. Field SK, Fisher D, Jarand JM et al. New treatment options for multidrug-resistant tuberculosis. Ther Adv Respir Dis 2012; 6: 255-68.
6. Bate AB, Kalin JH, Fooksman EM et al. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg Med Chem Lett 2007; 17: 1346-8.
7. Garci A, Montaner PG, Abbate E et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-7.
8. Reddy VM, Einck L, Andries K et al. In vitro interactions between new antitubercular drug candidates. Antimicrob Agents Chemother 2010; 54: 2840-6.
9. Ordway D, Viveiros M, Leandro C et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-22.
10. Kristiansen JE, Amaral L. The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother 1997; 40: 319-27.
11. Chan YY, Ong YM, Chua KL. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother 2007; 51: 623-30.
12. Amaral L, Kristiansen JE, Abebe LS et al. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049-53.
13. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2000; 16: 69-71.
14. Amaral L, Kristiansen JE, Viveiros M et al. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother 2001; 47: 505-11.
15. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-8.
16. Kaatz GW, Moudgal VV, Seo SM et al. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 719-26.
17. Warman AJ, Rito TS, Fisher NE et al. Antitubercular pharmacodynamics of phenothiazines. J Antimicrob Chemother 2013; 68: 869-80.
18. Amaral L. Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Méd Port 2012; 25: 118-21.
19. Martins M, Schelz Z, Martins A et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 2007; 29: 338-40.
20. Pluta K, Morak-Mlodawska B, Jeleń M. Recent progress in biological activities of synthesized phenothiazines. Eur J Med Chem 2011; 46: 3179-89.
21. Jaszczyszyn A, Ga{ogonek}siorowski K, Świa{ogonek}tek P et al. Chemical structure of phenothiazines and their biological activity. Pharmacol Rep 2012; 64: 16-23.
22. Yano T, Li L-S, Weinstein E et al. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 2006; 281: 11456-63.
23. Wójcikowski J, Maurel P, Daniel WA. Autoinduction of the metabolism of phenothiazine neuroleptics in a primary culture of human hepatocytes. Pharmacol Rep 2012; 64: 1578-83.
24. Changsen C, Franzblau SG, Palittapongarnpim P. Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob Agents Chemother 2003; 47: 3682-7.
25. Madrid PB, Polgar WE, Toll L et al. Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg Med Chem Lett 2007; 17: 3014-7.
26. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376-80.
27. Ordway D, Vi M, Leandro C et al. Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. 2002; 20: 34-43.
28. Crowle AJ, Douvas GS, May MH. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38: 410-9.
29. Daniel WA, Wójcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol Appl Pharmacol 1999; 158: 115-24.
30. Amaral L, Martins A, Molnar J et al. Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo 2010; 24: 409-24.
31. Martins M, Viveiros M, Amaral L. Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 2008; 22: 69-75.
32. Welin A, Raffetseder J, Eklund D et al. Importance of phagosomal functionality for growth restriction of Mycobacterium tuberculosis in primary human macrophages. J Innate Immun 2011; 3: 508-18.
33. Malik ZA, Iyer SS, Kusner DJ et al. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages. J Immunol 2001; 166: 3392-401.